Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects from both sexes aged between 18 and 65 years;~* Patient diagnosed with mild depression episode confirmed by psychiatric and psychometric evaluation, presenting basal scores above 08 and below 24 measured by the Hamilton Rating Scale (HAM-D);~* Capable of understanding the nature and objective of the study, including risks and adverse effects and intended to cooperate with the researcher and act in accordance with the requirements of the entire protocol, which comes to be confirmed by signing the informed consent.~Exclusion Criteria:~* Have a known hypersensitivity to Trichilia catigua or history of serious adverse reactions;~* Shows risk of suicide, assault, murder or moral exposure;~* Clinical history of bleeding disorders;~* Drug addiction, including alcohol;~* Known or suspected neoplasia;~* Knowledge positive test result for the human immunodeficiency virus;~* Patient not willing to adhere to the procedures of the Protocol;~* For women, can not be pregnant or nursing and must be in use of a contraception method during the participation in the study;~* Patients using other drugs with sedative or antidepressant action, which can not be suspended for 15 days (wash out);~* Diabetics;~* Hyperthyroidism;~* Participation in any experimental study or use of any experimental drug three months before the start of this study;~* Has any condition which the investigator deems relevant to the non-participation of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram + LABCAT TCJUSS (Type: EXPERIMENTAL): Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
- Escitalopram + LABCAT TCJUSS placebo (Type: PLACEBO_COMPARATOR): Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
- Escitalopram Placebo + LABCAT TCJUSS (Type: EXPERIMENTAL): Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).

Based on this trial design, predict the completion outcome and termination type (if applicable).